文献速递妇科

高剂量(60 Gy)调强放疗联合同步每周顺铂后行腔内放疗治疗局部晚期宫颈癌:一项II期前瞻性临床试验

High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
PubMed 文献 · Gynecol Oncol · 2023-09-07

这项单中心II期前瞻性试验纳入88例FIGO II-IVa期宫颈癌患者,给予原发肿瘤及临床阳性淋巴结高剂量(60 Gy)调强放疗联合同步每周顺铂,随后行腔内放疗。30个月无进展生存率为82.8%,总生存率93.6%,3级及以上血液学毒性11例(12.5%),非血液学毒性3例(3.4%)。

要点

  • 30个月无进展生存率82.8%,总生存率93.6%,局部区域复发率8.2%,远处转移率9.2%。
  • 放疗期间MRI降期者30个月无复发生存率92.9% vs 未降期者73.1%(P=0.009),总生存率100% vs 87.0%(P=0.006)。
  • 3级及以上血液学毒性11例(12.5%),非血液学毒性3例(3.4%)。

核心结论

  • 高剂量(60 Gy)调强放疗联合同步每周顺铂治疗局部晚期宫颈癌获得了良好的无进展生存结局。
  • 放疗期间的肿瘤反应可作为无进展生存的重要预后因素。

研究设计与样本

  • II期前瞻性临床试验,单中心纳入88例FIGO II-IVa期宫颈癌患者。
  • 干预为原发肿瘤及临床阳性淋巴结接受高剂量(60 Gy)调强放疗联合同步每周顺铂,随后行腔内放疗。
  • 主要终点为30个月无进展生存率(目标值82%,较采用标准剂量放疗的GOG 120试验提高20%)。
  • 次要终点包括肿瘤反应、毒性、复发、远处转移和总生存。
  • 试验注册于ClinicalTrials.gov,标识号NCT02993653。

主要发现

  • 30个月无进展生存率为82.8%。
  • 30个月总生存率、局部区域复发率、远处转移率和腹主动脉旁复发率分别为93.6%、8.2%、9.2%和2.4%。
  • 88例患者中45例(51.1%)在放疗期间MRI显示降期,80例(90.9%)在高剂量调强放疗和腔内放疗后3个月达到临床完全缓解。
  • 放疗期间降期组较未降期组30个月无复发生存率(92.9% vs 73.1%,P=0.009)和总生存率(100% vs 87.0%,P=0.006)显著更高。
  • 3级及以上血液学毒性见于11例(12.5%)患者,3级及以上非血液学毒性见于3例(3.4%)患者。

关键数值与推荐

  • 主要终点30个月无进展生存率目标值为82%,较GOG 120试验采用标准剂量放疗提高20%。
  • 放疗期间降期组30个月无复发生存率92.9% vs 未降期组73.1%(P=0.009)。
  • 放疗期间降期组30个月总生存率100% vs 未降期组87.0%(P=0.006)。
  • 3级及以上血液学毒性发生率12.5%(11/88),3级及以上非血液学毒性发生率3.4%(3/88)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Radiotherapy dose-escalation using intensity-modulated radiotherapy (IMRT) has been necessary to improve treatment results in cervical cancer. METHODS: This was a phase II prospective clinical trial. 88 patients with FIGO II-IVa cervical cancer were enrolled in a single center. They received high-dose (60 Gy) IMRT with weekly cisplatin to the primary tumor and clinically positive nodes followed by intracavitary radiation. The primary endpoint was 30-month PFS rate (Target; 82%, an increase of 20% compared to GOG 120 trial using standard-dose radiotherapy). Secondary endpoints were tumor response, toxicity, recurrence, distant metastasis, and overall survival. RESULTS: Progression-free survival rate at 30 months was 82.8%. Overall survival, locoregional recurrence, distant metastasis, and para-aortic recurrence rates at 30 months were 93.6%, 8.2%, 9.2%, and 2.4%, respectively. Forty-five (51.1%) of 88 patients achieved downstaging on MRI during radiotherapy and 80 (90.9%) patients had clinically complete response at three months after high-dose IMRT and intracavitary radiotherapy. The 30-month recurrence-free survival (92.9% vs. 73.1%, P = 0.009) and overall survival (100% vs. 87.0%, P = 0.006) were significantly higher in the downstaged group than in the non-downstaged group during radiotherapy. Grade 3 or higher hematologic toxicity was found in 11 (12.5%) patients and grade 3 or higher non-hematologic toxicity was found in 3 (3.4%) patients. Fourteen had chronic urinary (8.0%), intestinal (5.7%) toxicity, pelvic insufficiency fracture (2.3%) or vesicovaginal fistula (2.3%). CONCLUSION: High-dose (60 Gy) IMRT with concurrent weekly cisplatin in locally advanced cervical cancer yielded favorable progression-free survival outcome. Tumor response during radiotherapy can be a significant prognostic factor for PFS. CLINICAL TRIAL INFORMATION: This prospective trial is registered at ClinicalTrials.gov Identifier: NCT02993653.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee HC, Jeong JW, Lee JH, et al. High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial. Gynecol Oncol. 2023. PMID: 37689018. doi:10.1016/j.ygyno.2023.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。